Cargando…
New Indications for Dabigatran: A Suggestion from a Drug Use Evaluation Study
OBJECTIVE: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012. The objective of this study was to assess the rational drug use of dab...
Autores principales: | Ashrafi, Farzaneh, Rezaie, Najmeh, Mousavi, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787906/ https://www.ncbi.nlm.nih.gov/pubmed/29417080 http://dx.doi.org/10.4103/jrpp.JRPP_17_54 |
Ejemplares similares
-
Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline
por: Mousavi, Sarah, et al.
Publicado: (2016) -
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022) -
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
por: Malmström, Rickard E., et al.
Publicado: (2013) -
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
por: Ashrafi, Farzaneh, et al.
Publicado: (2018) -
The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)